Summit Therapeutics (SMMT) Accounts Payables (2018 - 2026)

Summit Therapeutics (SMMT) has reported Accounts Payables for 9 consecutive years, with $22.9 million the latest figure, recorded in Q2 2026.

• Quarterly Accounts Payables changed 0.37% year-over-year to $22.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $22.9 million (changed 0.37% YoY) and the FY2025 annual result came in at $20.3 million, up 337.7% from the prior year.
• Accounts Payables declined to $22.9 million in Q2 2026 per SMMT's latest filing, from $27.5 million in the prior quarter.
• Over the last five years, Accounts Payables for SMMT reached as high as $27.5 million in Q1 2026 and fell as low as $355000.0 in Q4 2022.
• A 5-year average of $8.8 million and a median of $4.1 million in 2022 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables tumbled 91.88% — and 2024, when it jumped 797.32%.
• Year by year, Accounts Payables stood at $355000.0 in 2022, then jumped by 651.27% to $2.7 million in 2023, then surged by 73.83% to $4.6 million in 2024, then jumped by 337.7% to $20.3 million in 2025, then advanced by 12.83% to $22.9 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $22.9 million, $27.5 million, and $20.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.